Skip to main content
Glama

nvd

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. v1 supports \"company\"."New value: +"Entity type: \"company\" or \"drug\"."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "drug"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker, CIK, or company name (e.g., \"AAPL\", \"0000320193\", \"Apple\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."
  3. Added

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description discloses multiple-match behavior ('returns `figi_candidates` to pick from'), failure representation ('stated explicitly under `unresolved`'), source labeling, ISIN-to-LEI routing, and graceful degradation when GLEIF/OpenFIGI are unavailable. It also notes internal cascading and that it replaces 2-3 manual lookups. This goes well beyond the existing annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and dense, but it is front-loaded with the core purpose and 'Use FIRST' guidance before diving into supported types and edge cases. Some parentheticals and repeated identifier lists add length, though they remain informative rather than filler.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity and absence of an output schema, the description is remarkably complete: it covers accepted inputs, output identifier kinds, provenance labeling, unresolved IDs, ambiguity handling, fallback behavior on upstream outages, and the two supported entity types. An agent has enough information to invoke it correctly without guessing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description adds substantial semantic value for the `value` parameter: ticker/CIK/ISIN/name forms, drug brand/generic names, and a critical caution to pass only the entity name, e.g., 'NEW YORK ST DORM AUTH' rather than a full noun phrase, with the reason trailing security-class words fail FIGI lookup.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It also provides concrete query examples and explicitly frames its position relative to siblings by noting other tools need the IDs it produces.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives an explicit directive: 'Use FIRST whenever you have a name but need an ID.' It also clarifies the supported entity types and when enrichment degrades gracefully. It does not name specific alternatives or state when not to use this tool, so it stops short of full exclusions.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All nvd toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4/5.0
Disambiguation4/5

Most tools have distinct purposes, but some overlap exists (e.g., ask_pipeworx and ask_pipeworx_grounded, deep_research and ask_pipeworx). The Polymarket tools are numerous but clearly differentiated.

Naming Consistency3/5

Mixed naming conventions: some tools start with verbs (ask_pipeworx, search_cves), others with nouns (entity_profile, recent_changes). Prefixes (pipeworx_, polymarket_) help but the pattern is not uniform.

Tool Count2/5

33 tools is excessive for a single server, covering too many domains (NVD, Pipeworx, Polymarket, SEC, memory). This reduces coherence and makes it hard for agents to navigate.

Completeness4/5

Core workflows are covered: CVE lookup, company research, prediction market analysis, and data querying. However, there are minor gaps (e.g., no tool for editing stored data, no CVE metrics beyond search).

Resources